Smithfield Trust Co Has $352,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Smithfield Trust Co lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,164 shares of the company’s stock after buying an additional 70 shares during the period. Smithfield Trust Co’s holdings in Zoetis were worth $352,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Zoetis in the third quarter valued at $31,000. First Personal Financial Services acquired a new stake in Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis in the third quarter valued at $33,000. Finally, Dunhill Financial LLC lifted its stake in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $166.96 on Thursday. The firm has a 50 day moving average of $166.57 and a 200-day moving average of $176.99. The stock has a market capitalization of $74.76 billion, a PE ratio of 30.52, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. Zoetis’s dividend payout ratio is currently 36.56%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of recent analyst reports. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Barclays raised their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Piper Sandler raised their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Finally, Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.